Skip to main content

Table 2 Multivariable Cox proportional hazards models for the combination of cumulative smoking consumption and pre-treatment EBV DNA

From: Combination of smoking and Epstein-Barr virus DNA is a predictor of poor prognosis for nasopharyngeal carcinoma: a long-term follow-up retrospective study

Variable

OSa

PFSb

LRFSc

DMFSd

HRe (95%CI)

P value

HR (95%CI)

P value

HR (95%CI)

P value

HR (95%CI)

P value

T stage (T4 vs. T1–3)

1.365 (1.012–1.840)

0.041

1.309 (1.027–1.668)

0.030

1.883 (1.219–2.907)

0.004

1.218 (0.874–1.696)

0.245

N stage (N2–3 vs. N0–1)

1.230 (0.906–1.670)

0.184

1.217 (0.950–1.559)

0.121

0.765 (0.497–1.175)

0.221

1.890 (1.310–2.726)

0.001

Combination of cumulative smoking consumption and pre-treatment EBVf

 

< 0.001

 

< 0.001

 

0.085

 

< 0.001

Group 1: < 30 pack-years and pre-treatment EBV < 1500

Reference

Reference

Reference

Reference

Group 2: ≥30 pack-years and pre-treatment EBV < 1500

1.836 (1.127–2.991)

0.015

1.394 (0.933–2.083)

0.105

0.806 (0.384–1.692)

0.568

1.090 (0.574–2.069)

0.792

Group 3: < 30 pack-years and pre-treatment EBV ≥ 1500

2.519 (1.703–3.728)

< 0.001

2.669 (1.974–3.608)

< 0.001

1.700 (1.035–2.793)

0.036

3.055 (2.012–4.639)

< 0.001

Group 4: ≥30 pack-years and pre-treatment EBV ≥ 1500

3.614 (2.308–5.658)

< 0.001

2.912 (2.010–4.219)

< 0.001

1.515 (0.770–2.981)

0.229

3.422 (2.058–5.691)

< 0.001

  1. aOS Overall survival
  2. bPFS Progression-free survival
  3. cDMFS Distant metastasis-free survival
  4. dLRFS Locoregional relapse-free survival
  5. eHR Hazard ratio
  6. fEBV Epstein-Barr virus